Lilly Signs a License Agreement with Asahi Kasei Pharma for AK1780 to Treat Chronic Pain
Shots: Asahi Kasei to receive an $20M up front, ~$210M as development & regulatory milestones and will be eligible for ~$180M milestones along with royalties on sales of the therapy. Lilly to acquire the exclusive rights for AK1780 while Asahi Kasei will retain the right to promote AK1780 in Japan and China (including Hong Kong […]